Financhill
Sell
48

CHE Quote, Financials, Valuation and Earnings

Last price:
$575.81
Seasonality move :
2.38%
Day range:
$568.80 - $581.23
52-week range:
$512.12 - $623.61
Dividend yield:
0.33%
P/E ratio:
28.03x
P/S ratio:
3.48x
P/B ratio:
7.12x
Volume:
124.5K
Avg. volume:
145.7K
1-year change:
2.83%
Market cap:
$8.4B
Revenue:
$2.4B
EPS (TTM):
$20.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CHE
Chemed
$641.8M $5.55 9.18% 29.89% $677.33
ADUS
Addus HomeCare
$339.9M $1.33 22.1% 38.23% $135.70
AMED
Amedisys
$596.5M $1.11 4.11% 40.38% $96.86
HCAT
Health Catalyst
$79.2M $0.00 5.92% -99.77% $8.23
OPCH
Option Care Health
$1.3B $0.35 10.04% 33.23% $38.56
OPRX
OptimizeRx
$18.7M -$0.12 -5.1% -68.42% $10.83
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CHE
Chemed
$575.46 $677.33 $8.4B 28.03x $0.50 0.33% 3.48x
ADUS
Addus HomeCare
$105.00 $135.70 $1.9B 24.76x $0.00 0% 1.58x
AMED
Amedisys
$96.00 $96.86 $3.2B 35.42x $0.00 0% 1.34x
HCAT
Health Catalyst
$4.19 $8.23 $294.2M -- $0.00 0% 0.82x
OPCH
Option Care Health
$32.95 $38.56 $5.4B 26.57x $0.00 0% 1.08x
OPRX
OptimizeRx
$10.05 $10.83 $185.8M -- $0.00 0% 2.00x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CHE
Chemed
-- 0.460 -- 1.58x
ADUS
Addus HomeCare
18.37% 0.970 9.6% 1.50x
AMED
Amedisys
23.6% -0.140 12.01% 1.23x
HCAT
Health Catalyst
51.15% 1.824 84.45% 1.38x
OPCH
Option Care Health
45.12% 0.749 19.41% 0.91x
OPRX
OptimizeRx
21.91% -2.555 36.59% 2.77x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CHE
Chemed
$216.4M $94.8M 26.04% 26.04% 14.84% $19.5M
ADUS
Addus HomeCare
$101.5M $26.9M 7.81% 8.62% 9.59% $8.7M
AMED
Amedisys
$260.7M $60.1M 5.72% 7.55% 16.41% -$5.1M
HCAT
Health Catalyst
$34.7M -$17.5M -10.81% -19.29% -16.02% -$8.4M
OPCH
Option Care Health
$263.1M $79.2M 8.53% 15.22% 5.76% -$16.6M
OPRX
OptimizeRx
$22M $3.6M -12.93% -16.71% 11.67% $78K

Chemed vs. Competitors

  • Which has Higher Returns CHE or ADUS?

    Addus HomeCare has a net margin of 11.09% compared to Chemed's net margin of 6.57%. Chemed's return on equity of 26.04% beat Addus HomeCare's return on equity of 8.62%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    ADUS
    Addus HomeCare
    34.15% $1.07 $1.2B
  • What do Analysts Say About CHE or ADUS?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.7%. On the other hand Addus HomeCare has an analysts' consensus of $135.70 which suggests that it could grow by 29.24%. Given that Addus HomeCare has higher upside potential than Chemed, analysts believe Addus HomeCare is more attractive than Chemed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    ADUS
    Addus HomeCare
    7 0 0
  • Is CHE or ADUS More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Addus HomeCare has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.958%.

  • Which is a Better Dividend Stock CHE or ADUS?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Addus HomeCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Addus HomeCare pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or ADUS?

    Chemed quarterly revenues are $646.9M, which are larger than Addus HomeCare quarterly revenues of $297.1M. Chemed's net income of $71.8M is higher than Addus HomeCare's net income of $19.5M. Notably, Chemed's price-to-earnings ratio is 28.03x while Addus HomeCare's PE ratio is 24.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.48x versus 1.58x for Addus HomeCare. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.48x 28.03x $646.9M $71.8M
    ADUS
    Addus HomeCare
    1.58x 24.76x $297.1M $19.5M
  • Which has Higher Returns CHE or AMED?

    Amedisys has a net margin of 11.09% compared to Chemed's net margin of 10.26%. Chemed's return on equity of 26.04% beat Amedisys's return on equity of 7.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    AMED
    Amedisys
    43.84% $1.84 $1.6B
  • What do Analysts Say About CHE or AMED?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.7%. On the other hand Amedisys has an analysts' consensus of $96.86 which suggests that it could grow by 0.89%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    AMED
    Amedisys
    0 9 1
  • Is CHE or AMED More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Amedisys has a beta of 0.964, suggesting its less volatile than the S&P 500 by 3.612%.

  • Which is a Better Dividend Stock CHE or AMED?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or AMED?

    Chemed quarterly revenues are $646.9M, which are larger than Amedisys quarterly revenues of $594.8M. Chemed's net income of $71.8M is higher than Amedisys's net income of $61M. Notably, Chemed's price-to-earnings ratio is 28.03x while Amedisys's PE ratio is 35.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.48x versus 1.34x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.48x 28.03x $646.9M $71.8M
    AMED
    Amedisys
    1.34x 35.42x $594.8M $61M
  • Which has Higher Returns CHE or HCAT?

    Health Catalyst has a net margin of 11.09% compared to Chemed's net margin of -25.97%. Chemed's return on equity of 26.04% beat Health Catalyst's return on equity of -19.29%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    HCAT
    Health Catalyst
    43.58% -$0.33 $747.6M
  • What do Analysts Say About CHE or HCAT?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.7%. On the other hand Health Catalyst has an analysts' consensus of $8.23 which suggests that it could grow by 96.36%. Given that Health Catalyst has higher upside potential than Chemed, analysts believe Health Catalyst is more attractive than Chemed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    HCAT
    Health Catalyst
    7 4 0
  • Is CHE or HCAT More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.873%.

  • Which is a Better Dividend Stock CHE or HCAT?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or HCAT?

    Chemed quarterly revenues are $646.9M, which are larger than Health Catalyst quarterly revenues of $79.6M. Chemed's net income of $71.8M is higher than Health Catalyst's net income of -$20.7M. Notably, Chemed's price-to-earnings ratio is 28.03x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.48x versus 0.82x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.48x 28.03x $646.9M $71.8M
    HCAT
    Health Catalyst
    0.82x -- $79.6M -$20.7M
  • Which has Higher Returns CHE or OPCH?

    Option Care Health has a net margin of 11.09% compared to Chemed's net margin of 3.51%. Chemed's return on equity of 26.04% beat Option Care Health's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    OPCH
    Option Care Health
    19.73% $0.28 $2.5B
  • What do Analysts Say About CHE or OPCH?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.7%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 17.01%. Given that Chemed has higher upside potential than Option Care Health, analysts believe Chemed is more attractive than Option Care Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    OPCH
    Option Care Health
    6 1 0
  • Is CHE or OPCH More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.686%.

  • Which is a Better Dividend Stock CHE or OPCH?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or OPCH?

    Chemed quarterly revenues are $646.9M, which are smaller than Option Care Health quarterly revenues of $1.3B. Chemed's net income of $71.8M is higher than Option Care Health's net income of $46.7M. Notably, Chemed's price-to-earnings ratio is 28.03x while Option Care Health's PE ratio is 26.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.48x versus 1.08x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.48x 28.03x $646.9M $71.8M
    OPCH
    Option Care Health
    1.08x 26.57x $1.3B $46.7M
  • Which has Higher Returns CHE or OPRX?

    OptimizeRx has a net margin of 11.09% compared to Chemed's net margin of -0.24%. Chemed's return on equity of 26.04% beat OptimizeRx's return on equity of -16.71%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    OPRX
    OptimizeRx
    68.15% -- $149.8M
  • What do Analysts Say About CHE or OPRX?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.7%. On the other hand OptimizeRx has an analysts' consensus of $10.83 which suggests that it could grow by 2.82%. Given that Chemed has higher upside potential than OptimizeRx, analysts believe Chemed is more attractive than OptimizeRx.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    OPRX
    OptimizeRx
    4 1 0
  • Is CHE or OPRX More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.349%.

  • Which is a Better Dividend Stock CHE or OPRX?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or OPRX?

    Chemed quarterly revenues are $646.9M, which are larger than OptimizeRx quarterly revenues of $32.3M. Chemed's net income of $71.8M is higher than OptimizeRx's net income of -$78K. Notably, Chemed's price-to-earnings ratio is 28.03x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.48x versus 2.00x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.48x 28.03x $646.9M $71.8M
    OPRX
    OptimizeRx
    2.00x -- $32.3M -$78K

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Salesforce Stock Drop After a Strong Quarter?
Why Did Salesforce Stock Drop After a Strong Quarter?

Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Sell
4
CABO alert for May 3

Cable One [CABO] is down 41.98% over the past day.

Buy
55
PDEX alert for May 3

Pro-Dex [PDEX] is down 32.02% over the past day.

Buy
91
TRUP alert for May 3

Trupanion [TRUP] is up 23.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock